

EXHIBIT A

[Hillner BE, Siegel BA, Hanna L, et al. ^{18}F -fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. J Nucl Med 2015;56:222-228.]

Published results of NOPR:

Clinical Impact of Na¹⁸F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians

(n = 7154 January 31st 2011 – January 27th 2012) (n = 7794 January 28th 2012 – December 31st, 2012)
 ~ 50 of the 633 total participating centers performed 50% of the studies


Individual Na F PET-CT bone scintigraphy examinations performed for:

- (1) Initial staging (IS) n = 223
- (2) defining first osseous metastases (FOM) n = 653
- (3) Progressive skeletal metastatic disease (POM) n = 236


Other malignancies

Bladder, kidney, colorectal, lymphoma

Na F PET-CT bone scintigraphy impact on patient management



Impact of NaF PET-CT bone scintigraphy on future actions: Avoiding future diagnostic testing



Published results of NOPR:

Clinical Impact of Na¹⁸F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians


(n = 7154 January 31st 2011 – January 27th 2012) (n = 7794 January 28th 2012 – December 31st, 2012)
 ~ 50 of the 633 total participating centers performed 50% of the studies

Individual Na F PET-CT bone scintigraphy examinations performed for:


- (1) Initial staging (IS) n=1024
- (2) defining first osseous metastases (FOM) n = 1997
- (3) Progressive skeletal metastatic disease (POM) n = 510

Prostate carcinoma

Na F PET-CT bone scintigraphy impact on patient management



Impact of Na¹⁸F PET-CT bone scintigraphy on future actions: Avoiding future diagnostic testing



Published results of NOPR: Clinical Impact of Na¹⁸F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians

(n = 7154 January 31st 2011 – January 27th 2012) (n = 7794 January 28th 2012 – December 31st, 2012)
 ~ 50 of the 633 total participating centers performed 50% of the studies



Individual Na F PET-CT bone scintigraphy examinations performed for:

- (1) Initial staging (IS) n= 181
- (2) defining first osseous metastases (FOM) n = 781
- (3) Progressive skeletal metastatic disease (POM) n = 199

Impact of NaF PET-CT bone scintigraphy on future actions: Avoiding future diagnostic testing

Breast carcinoma

Na F PET-CT bone scintigraphy impact on patient management



Published results of NOPR:

Clinical Impact of Na¹⁸F PET-CT Bone Scintigraphy in Malignancy

Results of investigation defining clinical impact on decision making by referring and interpreting physicians


(n = 7154 January 31st 2011 – January 27th 2012) (n = 7794 January 28th 2012 – December 31st, 2012)
 ~ 50 of the 633 total participating centers performed 50% of the studies

Individual Na F PET-CT bone scintigraphy examinations performed for:

- (1) Initial staging (IS) n= 166
- (2) defining first osseous metastases (FOM) n = 380
- (3) Progressive skeletal metastatic disease (POM) n = 0

Lung carcinoma

Na F PET-CT bone scintigraphy impact on patient management



Impact of NaF PET-CT bone scintigraphy on future actions: Avoiding future diagnostic testing

